Thomas Paul

Thomas Paul

Company: Pfizer

Job title: Senior Director, Epigenetics Research

Seminars:

Discovery of a First-in-Class KAT6A/KAT6B Inhibitor CTX-648 (PF-9363) with Potent Anti-Tumor Activity in ER+ Breast Cancer with KAT6A Dysregulation 3:00 pm

Molecular dysregulation of KAT6A has been observed in several cancers, including amplifications in breast, lung, ovarian cancer along with oncogenic fusions in AML CTx-648 (PF-9363) is a first-in-class potent KAT6A/KAT6B inhibitor that possess high selectivity versus other MYST family members (KAT7, KAT5, KAT8) CTx-648 (PF-9363) inhibits expression of ESR1 expression leading to potent anti-tumor activity…Read more

day: Day One

Panel Discussion – HDAC3, BET, RNA, So Many Targets – Exploring New Potential in Well Known Targets to Create New Value & Diversify Pipelines 9:30 am

Discuss disease positioning and the importance of this in creating value out of your existing IP Highlight the criteria you should consider before exploring a new therapeutic area Explore current examples of therapeutics that have been reused in this way How can this potential be capitalized on for both oncological and non-oncological indications? Dr. NikhilRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.